CME Group price target lowered to $244 from $247 at Barclays

Barclays analyst Benjamin Budish lowered the firm’s price target on CME Group to $244 from $247 and keeps an Overweight rating on the shares. The company’s Q3 earnings beat by 2%, helped by non-transaction revenues and lower opex, but was slightly offset by lower non-operating income, the analyst tells investors in a research note. The firm says the biggest negative was the continued movement of collateral away from cash.